NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

NOVO.B.DK

480.3

+2.38%↑

GMAB.DK

1,311

-2.27%↓

ZEAL.DK

463.6

-10.76%↓

HLUNB.DK

33.78

-2.76%↓

AMBUB.DK

118.45

-0.04%↓

Search

Coloplast A-S (Class B)

Закрыт

727.4 0.86

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

722

Макс.

737.6

Ключевые показатели

By Trading Economics

Доход

-270M

1B

Продажи

73M

7B

P/E

Средняя по отрасли

33.45

73.239

Прибыль на акцию

6.38

Дивидендная доходность

3.03

Рентабельность продаж

14.859

Сотрудники

16,628

EBITDA

-42M

2.2B

Рекомендации

By TipRanks

Рекомендации

Нейтрально

Прогноз на 12 месяцев

+11.86% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

3.03%

3.06%

Следующий отчет о доходах

6 мая 2025 г.

Следующая эксдивидендная дата

12 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

164B

Предыдущая цена открытия

726.54

Предыдущая цена закрытия

727.4

Coloplast A-S (Class B) График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

31 мар. 2025 г., 22:45 UTC

Главные новости

Intel's New CEO Plots Turnaround; 'We Need to Improve'

31 мар. 2025 г., 23:54 UTC

Обсуждения рынка

Nikkei May Rise After Monday's Selloff -- Market Talk

31 мар. 2025 г., 23:44 UTC

Обсуждения рынка

Gold Edges Higher Amid Prospects of Broader, Higher U.S. Tariffs -- Market Talk

31 мар. 2025 г., 23:15 UTC

Обсуждения рынка

Tower Shares Ease After Bain Capital Exit -- Market Talk

31 мар. 2025 г., 23:15 UTC

Обсуждения рынка

Global Equities Roundup: Market Talk

31 мар. 2025 г., 22:33 UTC

Главные новости

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- Update

31 мар. 2025 г., 22:28 UTC

Отчет

China Vanke: Weak China Real-Estate Market Weighed on Results >000002.SZ

31 мар. 2025 г., 22:28 UTC

Отчет

China Vanke 2024 Loss CNY49.48B Vs. Net CNY12.16B >000002.SZ

31 мар. 2025 г., 22:28 UTC

Отчет

China Vanke 2024 Rev CNY343.18B Vs. CNY465.74B >000002.SZ

31 мар. 2025 г., 22:28 UTC

Отчет

China Vanke Swings to Loss for 2024 >000002.SZ

31 мар. 2025 г., 21:47 UTC

Главные новости

Intel's New CEO Says Turnaround 'Won't Be Easy' -- Barrons.com

31 мар. 2025 г., 21:44 UTC

Главные новости

Trump Administration Targets Harvard With Review of $9 Billion in Federal Funding -- WSJ

31 мар. 2025 г., 21:21 UTC

Обсуждения рынка

Intel Has 'A Lot of Hard Work Ahead' in Turnaround, CEO Says -- Market Talk

31 мар. 2025 г., 21:18 UTC

Главные новости

Copper Is 2025's Hottest Commodity -- Update

31 мар. 2025 г., 21:09 UTC

Главные новости

Senate Aims to Advance Trump Tax Agenda While Postponing Spending-Cut Fight -- Update

31 мар. 2025 г., 21:02 UTC

Отчет

Freeport-McMoRan Sees 1Q Gold Sales 100,000 Ounces Below Previous Guidance of 225,000 Ounces >FCX

31 мар. 2025 г., 21:01 UTC

Отчет

Freeport-McMoRan Backs 1Q Consolidated Copper Sales of 850M Pounds >FCX

31 мар. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

31 мар. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

31 мар. 2025 г., 20:37 UTC

Главные новости

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 3rd Update

31 мар. 2025 г., 20:17 UTC

Главные новости

Dow Bounced Back After Tariff Concerns Hit Global Markets -- WSJ

31 мар. 2025 г., 20:13 UTC

Главные новости

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- 2nd Update

31 мар. 2025 г., 20:03 UTC

Главные новости

A Wild Quarter for U.S. Stocks Sends Investors Abroad -- Update

31 мар. 2025 г., 19:09 UTC

Обсуждения рынка

Oil At 5-Week High as Trump Makes More Sanction Threats -- Market Talk

31 мар. 2025 г., 18:56 UTC

Обсуждения рынка

U.S. Natural Gas Gains With Help From Weather -- Market Talk

31 мар. 2025 г., 18:54 UTC

Обсуждения рынка

Canadian Banks' Fundamentals to Support Credit Ratings Near Term -- Market Talk

31 мар. 2025 г., 18:40 UTC

Обсуждения рынка

Walmart's Low Income Consumer Appears Increasingly Strained -- Market Talk

31 мар. 2025 г., 18:34 UTC

Обсуждения рынка

Ball, Crown Won't Be Materially Hurt if Soda Kicked Off Food Stamps -- Market Talk

31 мар. 2025 г., 18:28 UTC

Обсуждения рынка

Gold Climbs to Close Out Quarter -- Market Talk

31 мар. 2025 г., 18:03 UTC

Главные новости

Dow Edges Higher, Tariff Concerns Drag Down Global Markets -- WSJ

Сравнение c конкурентами

Изменение цены

Coloplast A-S (Class B) Прогноз

Целевая цена

By TipRanks

11.86% рост

Прогноз на 12 месяцев

Средняя 901.38 DKK  11.86%

Максимум 1,056 DKK

Минимум 720 DKK

Основано на мнении 8 аналитиков Wall Street, спрогнозировавших целевые цены для Coloplast A-S (Class B) на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Нейтрально

8 ratings

2

Покупка

4

Удержание

2

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Coloplast A-S (Class B)

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.